Geron: 3 Key Takeaways for Long-Term Investors

Geron reported strong Q3 2026 results with RYTELO net product revenue rising 27% year-over-year to $60.1 million, driven by growing adoption in community oncology clinics. The company discontinued its Phase III myelofibrosis trial to focus on commercial priorities and plans a European launch in Germany by year-end using a capital-efficient model. With operating expenses down 9% and $339 million in cash reserves, management is positioned to pursue hematology acquisitions.